Project Grant R01HL174590
Award Date 8/22/25
Completion Date 7/31/30
Dollars Obligated $766K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- This federal Project Grant award of $761,028 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research will support a multi-site prospective study on hypoxemia during sleep in adults with sickle cell anemia (SCA). The study aims to examine the prevalence, clinical impact, and response to treatment of sleep-related hypoxemia in this patient population across four institutions, including both urban and rural sites. Key activities will involve...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $137,219 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Illinois in Chicago. The goal of this 5-year grant is to develop the skills of Dr. Santosh L. Saraf, a mid-career hematologist and physician-scientist, to mentor the next generation of junior investigators focused on sickle cell disease (SCD)-related research. The research aims to investigate genetic factors and the role of complement...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $731,130 to the Children's Hospital Medical Center to conduct a study titled "Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents with Asthma". The study aims to evaluate the effectiveness of a stepped-care mHealth intervention for improving adherence to daily inhaled corticosteroids in adolescents with asthma. The...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
- The federal Project Grant award in the amount of $503,870.00 was provided by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) to Drexel University. The award is focused on developing a mechanistic understanding of how fetal hemoglobin (HbF) modulates the polymerization of sickle cell hemoglobin (HbS), which is the root cause of sickle cell disease. The research aims to address critical knowledge gaps that limit the rational optimization of...
- This federal Project Grant award for $111,626.00 was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage populations and their role in pulmonary hypertension associated with sickle cell disease. The 2-year research project aims to determine if targeting iron release can modify CD169+ macrophages and adaptive immune cells, and if ablation of CD169+ macrophages can inhibit the progression of...
- This $146,013 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) will be used by The Medical College of Wisconsin, Inc. to establish a large patient cohort leveraging electronic health record and administrative claims data to determine the risks of cardiopulmonary and renal end organ complications and factors associated with frequent acute care use among individuals with sickle cell disease. The award period...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will support the development of a mathematical model to study the oxygen-dependent equilibrium solubility of sickle hemoglobin in single red blood cells. The $719,128 award has an ultimate completion date of May 31, 2029 and aims to address the unmet need for mechanistic models of...